Lexeo Therapeutics (LXEO) reported a net loss of $38.3 million, or $0.43 per basic and diluted share, for the third quarter of 2026. The company also released interim Phase I/II data for LX2020 in PKP2 arrhythmogenic cardiomyopathy.
Among seven participants in high-dose cohorts, LX2020 treatment was associated with an 80% mean reduction in non-sustained ventricular tachycardia and a 44% mean reduction in premature ventricular contractions at latest assessment. Lexeo said the FDA is open to non-sustained ventricular tachycardia as a primary surrogate endpoint in a potential accelerated-approval pivotal study.
- Cash, cash equivalents and investments totaled $219.1 million as of September 30, 2026, with operations expected to be funded into 2028.
- Research and development expense was $34.5 million, compared with $15.7 million a year earlier.
- General and administrative expense was $5.9 million, compared with $6.0 million a year earlier.
- Lexeo expects to finalize pivotal-study design details in the first half of 2027 and initiate the study in the second half of 2027.
- Ten participants had been dosed in the HEROIC-PKP2 Phase I/II trial, with nine reaching at least 12 months of follow-up as of October 15, 2026.
$LXEO Insider Trading Activity
$LXEO insiders have traded $LXEO stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $LXEO stock by insiders over the last 6 months:
- RICHARD NOLAN TOWNSEND (Chief Executive Officer) has made 0 purchases and 3 sales selling 32,634 shares for an estimated $149,731.
- NARINDER PAL BHALLA (Chief Medical Officer) sold 22,306 shares for an estimated $98,592
- LOUIS EDWARD TAMAYO (Chief Financial Officer) has made 0 purchases and 2 sales selling 8,758 shares for an estimated $41,040.
- JOSE MANUEL OTERO (Chief Operating Officer) has made 0 purchases and 3 sales selling 7,272 shares for an estimated $33,974.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$LXEO Hedge Fund Activity
We have seen 83 institutional investors add shares of $LXEO stock to their portfolio, and 71 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 4,486,958 shares (+4659.8%) to their portfolio in Q3 2026, for an estimated $15,165,918
- PARADIGM BIOCAPITAL ADVISORS LP removed 2,008,752 shares (-32.5%) from their portfolio in Q2 2026, for an estimated $9,350,740
- POINT72 ASSET MANAGEMENT, L.P. removed 1,680,449 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $7,822,490
- AFFINITY ASSET ADVISORS, LLC added 1,438,000 shares (+24.8%) to their portfolio in Q3 2026, for an estimated $4,860,440
- MILLENNIUM MANAGEMENT LLC added 1,220,842 shares (+75.7%) to their portfolio in Q2 2026, for an estimated $5,683,019
- OCTAGON CAPITAL ADVISORS LP removed 1,100,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $5,120,500
- AVORO CAPITAL ADVISORS LLC removed 964,189 shares (-64.7%) from their portfolio in Q3 2026, for an estimated $3,258,958
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.